


### NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Single Technology Appraisal**

# Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487

### **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Leith Healthcare (glycopyrronium	All Wales Therapeutics and Toxicology
bromide cream)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
British Skin Foundation	Wales
Hyperhidrosis UK	British National Formulary
South Asian Health Foundation	Care Quality Commission
Specialised Healthcare Alliance	Department of Health - Northern Ireland
	Healthcare Improvement Scotland
Healthcare professional groups	Medicines and Healthcare products
British Association of Dermatologists	Regulatory Agency
British Dermatological Nursing Society	National Association of Primary Care
Primary Care Dermatology Society	National Pharmacy Association
Royal College of General Practitioners	NHS Confederation
Royal College of Nursing	Scottish Medicines Consortium
Royal College of Pathologists	Welsh Government
Royal College of Physicians	Welsh Health Specialised Services
Royal College of Surgeons Royal Pharmacoutical Society	Committee
Royal Pharmaceutical Society  Royal Society of Madicine	Descible comparator companies
Royal Society of Medicine	<ul><li>Possible comparator companies</li><li>Abbvie (botulinum toxin type A)</li></ul>
UK Clinical Pharmacy Association	Dermal Laboratories (aluminium)
Others	chloride hexahydrate)
Department of Health and Social Care	Grunenthal Meds (propantheline
NHS England	bromide)
TWI IO Eligiana	biolinas)
	Relevant research groups
	Cochrane Skin Group
	Genomics England
	MRC Clinical Trials Unit
	National Institute for Health Research
	Associated Public Health groups
	Public Health Wales
	UK Health Security Agency



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.